194 related articles for article (PubMed ID: 33588158)
21. PD-L1 expression correlates with tumor-infiltrating lymphocytes and better prognosis in patients with HPV-negative head and neck squamous cell carcinomas.
Sanchez-Canteli M; Granda-Díaz R; Del Rio-Ibisate N; Allonca E; López-Alvarez F; Agorreta J; Garmendia I; Montuenga LM; García-Pedrero JM; Rodrigo JP
Cancer Immunol Immunother; 2020 Oct; 69(10):2089-2100. PubMed ID: 32448984
[TBL] [Abstract][Full Text] [Related]
22. Programmed death ligand 1/indoleamine 2,3-dioxygenase 1 expression and tumor-infiltrating lymphocyte status in renal cell carcinoma with sarcomatoid changes and rhabdoid features.
Kiyozawa D; Takamatsu D; Kohashi K; Kinoshita F; Ishihara S; Toda Y; Eto M; Oda Y
Hum Pathol; 2020 Jul; 101():31-39. PubMed ID: 32360490
[TBL] [Abstract][Full Text] [Related]
23. Immunologic Characterization and T cell Receptor Repertoires of Expanded Tumor-infiltrating Lymphocytes in Patients with Renal Cell Carcinoma.
Lee MH; Theodoropoulos J; Huuhtanen J; Bhattacharya D; Järvinen P; Tornberg S; Nísen H; Mirtti T; Uski I; Kumari A; Peltonen K; Draghi A; Donia M; Kreutzman A; Mustjoki S
Cancer Res Commun; 2023 Jul; 3(7):1260-1276. PubMed ID: 37484198
[TBL] [Abstract][Full Text] [Related]
24. Multidiscipline Immunotherapy-Based Rational Combinations for Robust and Durable Efficacy in Brain Metastases from Renal Cell Carcinoma.
Lee HW
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34208157
[TBL] [Abstract][Full Text] [Related]
25. Association between Tumor Mutational Burden, Stromal CD8
Ruan H; Oike T; Sato H; Ando K; Ohno T
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831552
[TBL] [Abstract][Full Text] [Related]
26. PD-1/PD-L1 expression in a series of intracranial germinoma and its association with Foxp3+ and CD8+ infiltrating lymphocytes.
Liu B; Arakawa Y; Yokogawa R; Tokunaga S; Terada Y; Murata D; Matsui Y; Fujimoto KI; Fukui N; Tanji M; Mineharu Y; Minamiguchi S; Miyamoto S
PLoS One; 2018; 13(4):e0194594. PubMed ID: 29617441
[TBL] [Abstract][Full Text] [Related]
27. Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer.
Mansfield AS; Aubry MC; Moser JC; Harrington SM; Dronca RS; Park SS; Dong H
Ann Oncol; 2016 Oct; 27(10):1953-8. PubMed ID: 27502709
[TBL] [Abstract][Full Text] [Related]
28. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
[TBL] [Abstract][Full Text] [Related]
29. Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast.
Kim M; Chung YR; Kim HJ; Woo JW; Ahn S; Park SY
Breast Cancer Res; 2020 Mar; 22(1):32. PubMed ID: 32216826
[TBL] [Abstract][Full Text] [Related]
30. Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases.
Harter PN; Bernatz S; Scholz A; Zeiner PS; Zinke J; Kiyose M; Blasel S; Beschorner R; Senft C; Bender B; Ronellenfitsch MW; Wikman H; Glatzel M; Meinhardt M; Juratli TA; Steinbach JP; Plate KH; Wischhusen J; Weide B; Mittelbronn M
Oncotarget; 2015 Dec; 6(38):40836-49. PubMed ID: 26517811
[TBL] [Abstract][Full Text] [Related]
31. Characterization of tumor-infiltrating lymphocyte subsets from human renal cell carcinoma: specific reactivity defined by cytotoxicity, interferon-gamma secretion, and proliferation.
Finke JH; Rayman P; Hart L; Alexander JP; Edinger MG; Tubbs RR; Klein E; Tuason L; Bukowski RM
J Immunother Emphasis Tumor Immunol; 1994 Feb; 15(2):91-104. PubMed ID: 7907918
[TBL] [Abstract][Full Text] [Related]
32. Deciphering Microenvironment of NSCLC based on CD8+ TIL Density and PD-1/PD-L1 Expression.
Lin Z; Gu J; Cui X; Huang L; Li S; Feng J; Liu B; Zhou Y
J Cancer; 2019; 10(1):211-222. PubMed ID: 30662542
[No Abstract] [Full Text] [Related]
33. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
34. Natural immune reactivity-associated therapeutic response in patients with metastatic renal cell carcinoma receiving tumor-infiltrating lymphocytes and interleukin-2-based therapy.
Belldegrun A; Tso CL; Kaboo R; Pang S; Pierce W; deKernion JB; Figlin R
J Immunother Emphasis Tumor Immunol; 1996 Mar; 19(2):149-61. PubMed ID: 8732698
[TBL] [Abstract][Full Text] [Related]
35. Discordance of immunotherapy response predictive biomarkers between primary lesions and paired metastases in tumours: A systematic review and meta-analysis.
Zou Y; Hu X; Zheng S; Yang A; Li X; Tang H; Kong Y; Xie X
EBioMedicine; 2021 Jan; 63():103137. PubMed ID: 33310681
[TBL] [Abstract][Full Text] [Related]
36. Study of tumor-infiltrating lymphocytes for adoptive therapy of renal cell carcinoma (RCC) and metastatic melanoma: sequential proliferation of cytotoxic natural killer and noncytotoxic T cells in RCC.
Hayakawa K; Salmeron MA; Parkinson DR; Markowitz AB; von Eschenbach AC; Legha SS; Balch CM; Ross MI; Augustus LB; Itoh K
J Immunother (1991); 1991 Oct; 10(5):313-25. PubMed ID: 1790139
[TBL] [Abstract][Full Text] [Related]
37. Different expression of Fas and Fas ligand in tumor infiltrating and peripheral lymphocytes of patients with renal cell carcinomas.
Elsässer-Beile U; Gierschner D; Welchner T; Wetterauer U
Anticancer Res; 2003; 23(1A):433-7. PubMed ID: 12680244
[TBL] [Abstract][Full Text] [Related]
38. Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases.
Schoenfeld DA; Moutafi M; Martinez S; Djureinovic D; Merkin RD; Adeniran A; Braun DA; Signoretti S; Choueiri TK; Parisi F; Hurwitz M; Rimm DL; Wei W; Jilaveanu L; Kluger HM
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586773
[TBL] [Abstract][Full Text] [Related]
39. Flow cytometric analysis of tumour-infiltrating lymphocytes in patients with renal cell carcinoma.
Kowalczyk D; Skorupski W; Kwias Z; Nowak J
Br J Urol; 1997 Oct; 80(4):543-7. PubMed ID: 9352689
[TBL] [Abstract][Full Text] [Related]
40. Semiquantitative analysis of Th1 and Th2 cytokine expression in CD3+, CD4+, and CD8+ renal-cell-carcinoma-infiltrating lymphocytes.
Elsässer-Beile U; Grussenmeyer T; Gierschner D; Schmoll B; Schultze-Seemann W; Wetterauer U; Schulte Mönting J
Cancer Immunol Immunother; 1999 Jul; 48(4):204-8. PubMed ID: 10431690
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
